Gosset RyboDyn General Information
RyboDyn has discovered over 8,000 previously unknown protein fragments using its proprietary technology—about a thousand of which are specific to cancer cells. These discoveries enable the development of highly targeted immunotherapies with potential applications across multiple cancer types. The company recently closed a $4 million pre-seed round to advance its drug development efforts and expand partnerships. Independent validation supports the therapeutic potential of their novel targets.
Contact Information
Drug Pipeline
No pipeline data available
Key Partnerships
SOSV IndieBio accelerator, collaborations with Oregon Health & Science University for IP licensing, academic collaborations with Moffitt Cancer Center for independent validation, seeking further biopharma partners for pipeline advancement.
RyboDyn Funding
No funding data available